CompletedNot Applicable

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

United States20,830 participantsStarted 2009-02

Plain-language summary

To monitor the occurrence of invasive Hib disease over time and to determine product-specific rates of invasive Hib disease within the monitored population.

Who can participate

Age range59 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Residence within the geographic scope of Active Bacterial Core surveillance (ABCs) during the period of surveillance * Aged 0 through 59 months (prior to 5th birthday) on the day of inclusion for Hib disease surveillance and 2 through 23 months (prior to 2nd birthday) for Hib vaccine brand usage survey. * 2009-2014 calendar years inclusive. * For the Hib vaccine usage survey, agreement to complete the required survey. Exclusion Criteria: Not applicable.

What they're measuring

The rate of invasive Hib disease among persons within the population monitored by the Active Bacterial Core surveillance program.

Timeframe: Up to 6 years post vaccination

Trial details

NCT IDNCT00855855

SponsorSanofi Pasteur, a Sanofi Company

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2014-12

View on ClinicalTrials.gov More Haemophilus Infections trials